First manifestation of AQP4-IgG-positive neuromyelitis optica spectrum disorder following the COVID-19 mRNA vaccine BNT162b2

BNT162b2 is one of the effective COVID-19 vaccines. However, some researchers have also reported some neurological adverse events after the vaccination. Here, we present a case of a 52-year-old female who developed aquaporin (AQP) 4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) 14 days...

Descripción completa

Detalles Bibliográficos
Autores principales: Umezawa, Shu, Ioka, Katsura, Aizawa, Satoshi, Tashiro, Yuichi, Yoshizawa, Kazuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Covid-19
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9607809/
https://www.ncbi.nlm.nih.gov/pubmed/36289118
http://dx.doi.org/10.1007/s10072-022-06465-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9607809/
https://www.ncbi.nlm.nih.gov/pubmed/36289118
http://dx.doi.org/10.1007/s10072-022-06465-2

Ejemplares similares